{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T21:31:44Z","timestamp":1778189504523,"version":"3.51.4"},"reference-count":41,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,21]],"date-time":"2023-01-21T00:00:00Z","timestamp":1674259200000},"content-version":"am","delay-in-days":385,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.vaccine.2021.12.057","type":"journal-article","created":{"date-parts":[[2021,12,30]],"date-time":"2021-12-30T00:36:30Z","timestamp":1640824590000},"page":"714-725","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Intranasal immunization with a Middle East respiratory syndrome-coronavirus antigen conjugated to the M-cell targeting ligand Co4B enhances antigen-specific mucosal and systemic immunity and protects against infection"],"prefix":"10.1016","volume":"40","author":[{"given":"Ye Lin","family":"Yang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ju","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0008-9928","authenticated-orcid":false,"given":"Yongsu","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1675-4224","authenticated-orcid":false,"given":"Yong-Suk","family":"Jang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9997","key":"10.1016\/j.vaccine.2021.12.057_b0005","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/S0140-6736(15)60454-8","article-title":"Middle East respiratory syndrome","volume":"386","author":"Zumla","year":"2015","journal-title":"The Lancet"},{"issue":"10229","key":"10.1016\/j.vaccine.2021.12.057_b0010","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1016\/S0140-6736(19)33221-0","article-title":"Middle East respiratory syndrome","volume":"395","author":"Memish","year":"2020","journal-title":"The Lancet"},{"issue":"7440","key":"10.1016\/j.vaccine.2021.12.057_b0015","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/nature12005","article-title":"Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC","volume":"495","author":"Raj","year":"2013","journal-title":"Nature"},{"issue":"7592","key":"10.1016\/j.vaccine.2021.12.057_b0020","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1038\/nature16988","article-title":"Cryo-electron microscopy structure of a coronavirus spike glycoprotein trimer","volume":"531","author":"Walls","year":"2016","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.vaccine.2021.12.057_b0025","doi-asserted-by":"crossref","first-page":"4953","DOI":"10.1128\/JVI.00161-14","article-title":"Receptor variation and susceptibility to Middle East respiratory syndrome coronavirus infection","volume":"88","author":"Barlan","year":"2014","journal-title":"J Virol"},{"issue":"16","key":"10.1016\/j.vaccine.2021.12.057_b0030","doi-asserted-by":"crossref","first-page":"9220","DOI":"10.1128\/JVI.00676-14","article-title":"Host species restriction of Middle East respiratory syndrome coronavirus through its receptor, dipeptidyl peptidase 4","volume":"88","author":"van Doremalen","year":"2014","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2021.12.057_b0035","first-page":"279","article-title":"Nasal vaccine delivery. Micro and Nanotechnology in Vaccine Development","author":"Ramvikas","year":"2017","journal-title":"Elsevier"},{"issue":"1-3","key":"10.1016\/j.vaccine.2021.12.057_b0040","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S0169-409X(01)00166-1","article-title":"Intranasal vaccination against plague, tetanus and diphtheria","volume":"51","author":"Alpar","year":"2001","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.vaccine.2021.12.057_b0045","first-page":"1","article-title":"Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009","volume":"58","author":"Fiore","year":"2009","journal-title":"MMWR Recomm Rep"},{"issue":"5","key":"10.1016\/j.vaccine.2021.12.057_b0050","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/j.1399-302X.2006.00302.x","article-title":"Immune response in humans to a nasal boost with Streptococcus mutans antigens","volume":"21","author":"Childers","year":"2006","journal-title":"Oral Microbiol Immunol"},{"issue":"1","key":"10.1016\/j.vaccine.2021.12.057_b0055","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jri.2010.02.003","article-title":"Antibody-mediated protection and the mucosal immune system of the genital tract: relevance to vaccine design","volume":"85","author":"Mestecky","year":"2010","journal-title":"J Reprod Immunol"},{"issue":"12","key":"10.1016\/j.vaccine.2021.12.057_b0060","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1164\/rccm.201011-1783OC","article-title":"Potential of nasopharynx-associated lymphoid tissue for vaccine responses in the airways","volume":"183","author":"Brandtzaeg","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"issue":"10","key":"10.1016\/j.vaccine.2021.12.057_b0065","doi-asserted-by":"crossref","first-page":"5787","DOI":"10.4049\/jimmunol.0903184","article-title":"The M cell-targeting ligand promotes antigen delivery and induces antigen-specific immune responses in mucosal vaccination","volume":"185","author":"Kim","year":"2010","journal-title":"J Immunol"},{"issue":"1-2","key":"10.1016\/j.vaccine.2021.12.057_b0070","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.vetmic.2015.03.005","article-title":"Nasal immunization with M cell-targeting ligand-conjugated ApxIIA toxin fragment induces protective immunity against Actinobacillus pleuropneumoniae infection in a murine model","volume":"177","author":"Park","year":"2015","journal-title":"Vet Microbiol"},{"issue":"3","key":"10.1016\/j.vaccine.2021.12.057_b0075","doi-asserted-by":"crossref","first-page":"427","DOI":"10.4014\/jmb.1910.10055","article-title":"Middle East respiratory syndrome-coronavirus infection into established hDPP4-transgenic mice accelerates lung damage via activation of the pro-inflammatory response and pulmonary fibrosis","volume":"30","author":"Kim","year":"2020","journal-title":"J Microbiol Biotechnol"},{"issue":"46","key":"10.1016\/j.vaccine.2021.12.057_b0080","doi-asserted-by":"crossref","first-page":"6170","DOI":"10.1016\/j.vaccine.2014.08.086","article-title":"Searching for an ideal vaccine candidate among different MERS coronavirus receptor-binding fragments\u2014the importance of immunofocusing in subunit vaccine design","volume":"32","author":"Ma","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.12.057_b0085","doi-asserted-by":"crossref","DOI":"10.4014\/jmb.1908.08004","article-title":"Middle East respiratory syndrome coronavirus-encoded accessory proteins impair MDA5-and TBK1-mediated activation of NF-\u03baB","author":"Lee","year":"2019282981316","journal-title":"J Microbiol Biotechnol"},{"issue":"1","key":"10.1016\/j.vaccine.2021.12.057_b0090","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1128\/JVI.02129-14","article-title":"The human CD8+ T cell responses induced by a live attenuated tetravalent dengue vaccine are directed against highly conserved epitopes","volume":"89","author":"Weiskopf","year":"2015","journal-title":"J Virol"},{"issue":"9","key":"10.1016\/j.vaccine.2021.12.057_b0095","doi-asserted-by":"crossref","first-page":"4589","DOI":"10.1128\/jvi.64.9.4589-4592.1990","article-title":"Effective clearance of mouse hepatitis virus from the central nervous system requires both CD4+ and CD8+ T cells","volume":"64","author":"Williamson","year":"1990","journal-title":"J Virol"},{"issue":"1","key":"10.1016\/j.vaccine.2021.12.057_b0100","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1146\/annurev.immunol.18.1.275","article-title":"CD8+ T cell effector mechanisms in resistance to infection","volume":"18","author":"Harty","year":"2000","journal-title":"Annu Rev Immunol"},{"issue":"1-2","key":"10.1016\/j.vaccine.2021.12.057_b0105","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S0022-1759(03)00265-5","article-title":"Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation","volume":"281","author":"Betts","year":"2003","journal-title":"J Immunol Methods"},{"issue":"11","key":"10.1016\/j.vaccine.2021.12.057_b0110","doi-asserted-by":"crossref","first-page":"5954","DOI":"10.4049\/jimmunol.168.11.5954","article-title":"Characterization of CD4+ CTLs ex vivo","volume":"168","author":"Appay","year":"2002","journal-title":"J Immunol"},{"issue":"3","key":"10.1016\/j.vaccine.2021.12.057_b0115","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.4049\/jimmunol.173.3.1834","article-title":"Emergence of a CD4+ CD28- granzyme B+, cytomegalovirus-specific T cell subset after recovery of primary cytomegalovirus infection","volume":"173","author":"van Leeuwen","year":"2004","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2021.12.057_b0120","doi-asserted-by":"crossref","first-page":"194","DOI":"10.3389\/fimmu.2017.00194","article-title":"CD4 CTL, a cytotoxic subset of CD4+ T cells, their differentiation and function","volume":"8","author":"Takeuchi","year":"2017","journal-title":"Front Immunol"},{"issue":"28","key":"10.1016\/j.vaccine.2021.12.057_b0125","doi-asserted-by":"crossref","first-page":"8738","DOI":"10.1073\/pnas.1510830112","article-title":"Pre-and postexposure efficacy of fully human antibodies against Spike protein in a novel humanized mouse model of MERS-CoV infection","volume":"112","author":"Pascal","year":"2015","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2021.12.057_b0130","doi-asserted-by":"crossref","first-page":"107051","DOI":"10.1016\/j.intimp.2020.107051","article-title":"The immune response and immune evasion characteristics in SARS-CoV, MERS-CoV, and SARS-CoV-2: Vaccine design strategies","volume":"92","author":"Molaei","year":"2021","journal-title":"Int Immunopharmacol"},{"issue":"18","key":"10.1016\/j.vaccine.2021.12.057_b0135","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1016\/j.vaccine.2014.02.004","article-title":"Intranasal vaccination with recombinant receptor-binding domain of MERS-CoV spike protein induces much stronger local mucosal immune responses than subcutaneous immunization: Implication for designing novel mucosal MERS vaccines","volume":"32","author":"Ma","year":"2014","journal-title":"Vaccine"},{"issue":"19","key":"10.1016\/j.vaccine.2021.12.057_b0140","doi-asserted-by":"crossref","first-page":"10777","DOI":"10.1128\/JVI.01756-13","article-title":"Crystal structure of the receptor-binding domain from newly emerged Middle East respiratory syndrome coronavirus","volume":"87","author":"Chen","year":"2013","journal-title":"J Virol"},{"issue":"7461","key":"10.1016\/j.vaccine.2021.12.057_b0145","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/nature12328","article-title":"Molecular basis of binding between novel human coronavirus MERS-CoV and its receptor CD26","volume":"500","author":"Lu","year":"2013","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.vaccine.2021.12.057_b0150","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1080\/21645515.2015.1021527","article-title":"Optimization of antigen dose for a receptor-binding domain-based subunit vaccine against MERS coronavirus","volume":"11","author":"Tang","year":"2015","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2021.12.057_b0155","first-page":"4956","article-title":"Middle East Respiratory Syndrome Coronavirus (MERS-CoV) infection: epidemiology, pathogenesis and clinical characteristics","volume":"22","author":"Nassar","year":"2018","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"10.1016\/j.vaccine.2021.12.057_b0160","doi-asserted-by":"crossref","first-page":"51","DOI":"10.4110\/in.2015.15.2.51","article-title":"Recent advances of vaccine adjuvants for infectious diseases","volume":"15","author":"Lee","year":"2015","journal-title":"Immune Netw"},{"issue":"1","key":"10.1016\/j.vaccine.2021.12.057_b0165","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1078\/1438-4221-00241","article-title":"Role of secretory antibodies in the defence against infections","volume":"293","author":"Brandtzaeg","year":"2003","journal-title":"Int J Med Microbiol"},{"key":"10.1016\/j.vaccine.2021.12.057_b0170","first-page":"1","article-title":"Cytotoxic CD4 T cells in antiviral immunity","volume":"2011","author":"Marshall","year":"2011","journal-title":"J Biomed Biotechnol"},{"issue":"12","key":"10.1016\/j.vaccine.2021.12.057_b0175","doi-asserted-by":"crossref","first-page":"6792","DOI":"10.1128\/JVI.07172-11","article-title":"Multifunctional CD4 cells expressing gamma interferon and perforin mediate protection against lethal influenza virus infection","volume":"86","author":"Brown","year":"2012","journal-title":"J Virol"},{"issue":"12","key":"10.1016\/j.vaccine.2021.12.057_b0180","doi-asserted-by":"crossref","first-page":"2679","DOI":"10.1099\/vir.0.055533-0","article-title":"Delayed induction of proinflammatory cytokines and suppression of innate antiviral response by the novel Middle East respiratory syndrome coronavirus: implications for pathogenesis and treatment","volume":"94","author":"Lau","year":"2013","journal-title":"J Gen Virol"},{"key":"10.1016\/j.vaccine.2021.12.057_b0185","first-page":"1","article-title":"A systematic review of SARS-CoV-2 vaccine candidates","volume":"5","author":"Dong","year":"2020","journal-title":"Signal Transduct Target Ther"},{"issue":"6506","key":"10.1016\/j.vaccine.2021.12.057_b0190","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1126\/science.abc7520","article-title":"Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model","volume":"369","author":"Rogers","year":"2020","journal-title":"Science"},{"issue":"9","key":"10.1016\/j.vaccine.2021.12.057_b0195","doi-asserted-by":"crossref","first-page":"6337","DOI":"10.4049\/jimmunol.181.9.6337","article-title":"Prior Immunization with severe acute respiratory syndrome (SARS)-associated coronavirus (SARS-CoV) nucleocapsid protein causes severe pneumonia in mice infected with SARS-CoV","volume":"181","author":"Yasui","year":"2008","journal-title":"J Immunol"},{"issue":"3","key":"10.1016\/j.vaccine.2021.12.057_b0200","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.coi.2013.03.011","article-title":"Th17 cell based vaccines in mucosal immunity","volume":"25","author":"Kumar","year":"2013","journal-title":"Curr Opin Immunol"},{"issue":"11","key":"10.1016\/j.vaccine.2021.12.057_b0205","doi-asserted-by":"crossref","first-page":"3858","DOI":"10.4049\/jimmunol.1700845","article-title":"Palmitate conditions macrophages for enhanced responses toward inflammatory stimuli via JNK activation","volume":"199","author":"Riera-Borrull","year":"2017","journal-title":"J Immunol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X21016650?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X21016650?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:06:04Z","timestamp":1759403164000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X21016650"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":41,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["S0264410X21016650"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2021.12.057","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intranasal immunization with a Middle East respiratory syndrome-coronavirus antigen conjugated to the M-cell targeting ligand Co4B enhances antigen-specific mucosal and systemic immunity and protects against infection","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2021.12.057","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}